Jcr Pharmaceuticals Co., Ltd. (4552) Press Release
Italfarmaco and JCR Pharmaceuticals Enter into Exclusive License Agreement for JR-141 in the United States, Europe, and Latin America
Filed with TSE ·
6ix hasn’t read this filing yet.
Earlier from Jcr Pharmaceuticals
- JCR Pharmaceuticals Receives Orphan Drug Designation from the Ministry of Health, Labour and Welfare of Japan for Givinostat for Duchenne Muscular Dystrophy
- FY2026 First Quarter Results Briefing Session Material
- JCR Pharmaceuticals - Notice Regarding the Completion of Payment for the Disposition of Treasury Stock as Restricted Stock Compensation
- JCR Pharmaceuticals Receives Marketing Authorization in the United Arab Emirates for IZCARGO™, a Blood-Brain Barrier-Penetrating Enzyme Replacement Therapy for Hunter Syndrome